A Research Study to Investigate How Well NNC0165-1875 in Combination With Semaglutide Works in People With Obesity
Public ClinicalTrials.gov record NCT04969939. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Investigation of Efficacy and Safety of NNC0165-1875 as add-on to Semaglutide for Weight Management in Subjects With Obesity
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The study is looking at a new medicine to help people lose weight. In this study participants will either get semaglutide and NNC0165-1875 or semaglutide and a "dummy" medicine (placebo). Which treatment participants get is decided by chance. Participants will get 2 injections per week, on the same day. Participants will have to take the study medicine by use of a pre-filled pen. A pen is a medical tool with a needle used for injections under the skin. The study doctor or staff will show participants how. The study will last for about 26 weeks. Participants will have 17 visits at the clinic with the study doctor. At 4 of the clinic visits participants cannot eat and drink (water is allowed until 2 hours prior to the visit) for 8 hours before the visit.Women: Women cannot take part if pregnant, breast-feeding or plan to become pregnant during the study period. Women who are able to become pregnant can participate if they agree to use contraception during the study.
Study identification
- NCT ID
- NCT04969939
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 120 participants
Conditions and interventions
Conditions
Interventions
- Semaglutide 2.4 mg and NNC0165-1875 2.0 mg Drug
- Semaglutide 2.4 mg and placebo 2.0 mg Drug
- Semaglutide 2.4 mg and NNC0165-1875 1.0 mg Drug
- Semaglutide 2.4 mg and placebo 1.0 mg Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 14, 2021
- Primary completion
- Dec 5, 2022
- Completion
- Jan 29, 2023
- Last update posted
- Jan 7, 2026
2021 – 2023
United States locations
- U.S. sites
- 25
- U.S. states
- 14
- U.S. cities
- 25
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Univ of Alabama Birmingham | Birmingham | Alabama | 35294 | — |
| Anaheim Clinical Trials, LLC | Anaheim | California | 92801 | — |
| Profil Institute For Clinical Research Inc | Chula Vista | California | 91911 | — |
| Velocity Clin Res Los Angeles | Los Angeles | California | 90017 | — |
| Diablo Clinical Research, Inc. | Walnut Creek | California | 94598 | — |
| Jacksonville Ctr For Clin Res | Jacksonville | Florida | 32216 | — |
| Endo Res Solutions Inc | Roswell | Georgia | 30076 | — |
| East West Med Res Inst | Honolulu | Hawaii | 96814 | — |
| Evanston Premier Hlthcr Res | Skokie | Illinois | 60077 | — |
| Altasciences Clinical Kansas, Inc. | Overland Park | Kansas | 66212 | — |
| L-MARC Research Center | Louisville | Kentucky | 40213 | — |
| AMC Community Endocrinology | Albany | New York | 12206 | — |
| NYC Research, Inc. | New York | New York | 10016 | — |
| PharmQuest Life Sciences LLC | Greensboro | North Carolina | 27408 | — |
| Accellacare | Wilmington | North Carolina | 28401 | — |
| Medical Uni of SC Charleston | Charleston | South Carolina | 29425 | — |
| Coastal Carolina Res Ctr. | North Charleston | South Carolina | 29405 | — |
| Texas Diabetes & Endocrinology, P.A._Austin | Austin | Texas | 78749 | — |
| Soltero Cardiovascular Research Center | Dallas | Texas | 75226 | — |
| Texas Diabetes & Endocrinology, P.A._Austin | Round Rock | Texas | 78681 | — |
| Chrysalis Clinical Research | St. George | Utah | 84790 | — |
| Washington Cntr Weight Mgmt | Arlington | Virginia | 22206 | — |
| Health Res of Hampton Roads | Newport News | Virginia | 23606 | — |
| National Clin Res Inc. | Richmond | Virginia | 23294 | — |
| Selma Medical Associates | Winchester | Virginia | 22601-3834 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04969939, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 7, 2026 · Synced Sep 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04969939 live on ClinicalTrials.gov.